About VGX Pharmaceuticals
VGX Pharmaceuticals is a company based in Blue Bell (United States) founded in 2002 was acquired by Inovio Pharmaceuticals in July 2008.. VGX Pharmaceuticals has raised $4.5 million across 4 funding rounds from investors including NIH, Korean Development Bank and Inovio Pharmaceuticals. VGX Pharmaceuticals operates in a competitive market with competitors including Novavax, Dyne Therapeutics, CureVac, Immunomic Therapeutics and Codagenix, among others.
- Headquarter Blue Bell, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.5 M (USD)
in 4 rounds
-
Latest Funding Round
$23.5 M (USD), Grant
Oct 01, 2008
-
Investors
NIH
& 3 more
-
Employee Count
Employee Count
-
Acquired by
Inovio Pharmaceuticals
(Jul 07, 2008)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of VGX Pharmaceuticals
VGX Pharmaceuticals has successfully raised a total of $4.5M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $23.5 million completed in October 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $23.5M
-
First Round
First Round
(15 May 2003)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2008 | Amount | Grant - VGX Pharmaceuticals | Valuation |
investors |
|
| Sep, 2007 | Amount | Series A - VGX Pharmaceuticals | Valuation |
investors |
|
| Feb, 2004 | Amount | Seed - VGX Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in VGX Pharmaceuticals
VGX Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Korean Development Bank and Inovio Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Development financing and commercial banking are provided in South Korea.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by VGX Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - VGX Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vgx Pharmaceuticals Comparisons
Competitors of VGX Pharmaceuticals
VGX Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novavax, Dyne Therapeutics, CureVac, Immunomic Therapeutics and Codagenix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| domain | founded_year | HQ Location |
Nucleic acid therapies for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics against cancer and infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Immunomic Therapeutics is engaged in developing nucleic acid immunotherapy platforms.
|
|
| domain | founded_year | HQ Location |
Live-attenuated viral vaccines are developed using proprietary SAVE technology.
|
|
| domain | founded_year | HQ Location |
Therapeutic vaccines for cancer and infectious diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about VGX Pharmaceuticals
When was VGX Pharmaceuticals founded?
VGX Pharmaceuticals was founded in 2002 and raised its 1st funding round 1 year after it was founded.
Where is VGX Pharmaceuticals located?
VGX Pharmaceuticals is headquartered in Blue Bell, United States. It is registered at Blue Bell, Pennsylvania, United States.
Is VGX Pharmaceuticals a funded company?
VGX Pharmaceuticals is a funded company, having raised a total of $4.5M across 4 funding rounds to date. The company's 1st funding round was a Seed of $499.84K, raised on May 15, 2003.
What does VGX Pharmaceuticals do?
VGX Pharmaceuticals was established in 2002 in Blue Bell, United States, within the biotechnology sector. Focus was placed on DNA-based vaccines targeting infectious diseases and cancers, alongside related devices. Key clinical programs encompassed Pennvax-B for HIV prevention, VGX-1027 for inflammatory conditions, VGX-3100 for cervical cancer treatment, and the Cellectra electroporator for DNA delivery. Operations concluded with a merger into Inovio Pharmaceuticals in July 2008.
Who are the top competitors of VGX Pharmaceuticals?
VGX Pharmaceuticals's top competitors include Dyne Therapeutics, Scancell and Novavax.
Who are VGX Pharmaceuticals's investors?
VGX Pharmaceuticals has 4 investors. Key investors include NIH, Korean Development Bank, Inovio Pharmaceuticals, and BioAdvance.